H1 2026 saw resilient performance with 1% organic revenue growth and stable margins despite market declines. Integration of OrthoLite is on track, supporting future growth and cost synergies, while strong cash flow and disciplined capital allocation underpin confidence in full-year and medium-term targets.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.